“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s358. https://doi.org/10.25251/skin.8.supp.358.